1992 - Deuringer F.U., Mueck A.O., Eicher W., Lippert T.H.: Cyclic vs. continuous transdermal estradiol replacement therapy and sequential oral chlormadinone acetate. Europ. Menopause Society, 2nd Congr., Madrid (Spain), Oct. 29-31, 1992; Abstract-Book No. 01 (2nd Expos.)


1992 - Deuringer F.U., Mueck A.O., Eicher W., Lippert T.H.: Estrogen deficiency-related sexual problems- treatment with the estradiol patch. 14th World Congr. Fertility Sterility, Caracas (Venezuela), Nov. 22-27, 1992; Abstract-Book No. 406


1992 - Deuringer F.U., Mueck A.O., Eicher W., Lippert T.H.: Zyklische vs. kontinuierliche transdermale Östradiol-Substitution und sequentielles niedrigdosiertes orales Norethisteronacetat. Menopausenkongress deutschsprachiger Länder, Wien (Österreich), 15.-17. Okt., 1992; Abstract-Book Nr. 04.


1992 - Deuringer F.U., Mueck A.O., Eicher W., Lippert T.H.:Sexuelle Beschwerden in der Peri- und Postmenopause- Wirksamkeit von Östradiol transdermal und Norethisteronacetat. Menopausenkongress deutschsprachiger Länder, Wien (Österreich), 15.-17. Oktober 1992; Abstract-Book Nr. 03.


1992 - Deuringer F.U., Salbach B., v. Holst T., Mueck A.O., Rabe T., Runnebaum B.: Einfluß von ESTRADERM TTS in Kombination mit zyklischer und kontinuierlicher Gabe von 1 mg Norethisteronacetat auf den Schilddrüsen-Stoffwechsel bei postmenopausalen Frauen. Deutsche Gesellschaft f. Gynäkol. u. Geburtshilfe, 49. Kongr., Berlin, 9-12. Sept. 1992; Abstract-Book Nr.P.02.45


1992 - Mueck A.O., Deuringer F.U., Lippert T.H.: Sequential norethisterone acetate 5 mg vs 1 mg orally with cyclic transdermal estradiol substitution. Europ. Menopause Society, 2nd Congr., Madrid (Spain), Oct. 29-31, 1992; Abstract-Book No. 03


1992 - Mueck A.O., Deuringer F.U., Lippert T.H.: Skin tolerability with the estradiol patch in 14.738 patients- Data from eight German multicentre studies. Europ. Menopause Society, 2nd Congr., Madrid (Spain), Oct. 29-31, 1992; Abstract-Book No. 04.


1993 - Deuringer F.U., Mueck A.O., Vidovic G., Labus M.: Intramuscular vs. oral progestogen continuously combined with transdermal estradiol. North American Menopause Society, 4th Congr., San Diego (USA), Sept. 2-4, 1993; Abstract-Book No. 11


1993 - Deuringer F.U., Mueck A.O., Weber E., Lippert T.H.: Efficacy of transdermal estradiol with different types of sequential oral progestins in urogenital disorders. Internat. Symposium on Women's Health in Menopause, Milano (Italy) Sept. 26-29, 1993; Abstract-Book p.53


1993 - Deuringer F.U., Mueck A.O., Weber E., Lippert T.H.: Efficacy of transdermal estradiol with different types of sequential oral progestins in urogenital disorders. Internat. Symposium on Women's Health in Menopause, Milano (Italy) Sept. 26-29, 1993; Abstract-Book p.53


1993 - Deuringer F.U., Mueck A.O.: Transdermal estradiol for preventing postmenopausal bone loss- biochemical markers correlated with bone density measurements. World Congr. Osteoporosis, 4th Internat.Symp.and Consensus Development Conference, Hongkong, March 27 - April 2, 1993; Gardiner-Caldwell Publications (ed. C.Christiansen), Abstract No. 182


1993 - Deuringer F.U., Salbach B., Rabe T. v.Holst T., Mueck A.O., Runnebaum B.: Long-term metabolic effects of transdermal estradiol treatment in postmenopausal women. 7th World Congr. Menopause, Stockholm (Sweden), June 20-24, 1993; Parthenon Publishing Carnforth (U.K.), Abstract-Book No. 259


1993 - Deuringer F.U., Salbach B., Rabe T. v.Holst T., Mueck A.O., Runnebaum B.: Long-term metabolic effects of transdermal estradiol treatment in postmenopausal women. 7th World Congr. Menopause, Stockholm (Sweden), June 20-24, 1993; Parthenon Publishing Carnforth (U.K.), Abstract-Book No. 259


1993 - Deuringer F.U., Seeger H., Mueck A.O., Korte K., LippertT.H.: Eicosanoid production in human umbilical cord vessels: Effect of natural and synthetic estrogens. 7th World Congress Menopause, Stockholm (Sweden), June 20-24, 1993; Parthenon Publishing Carnforth (U.K.), Abstract No. 298


1993 - Deuringer F.U., Seeger H., Mueck A.O., Korte K., Wiesner J., Lippert T.H.: Are vascular effects of 17ß-estradiol in postmenopausal women mediated via eicosanoid-metabolites? Internat. Symp. Women's Health in Menopause, Milano (Italy), Sept. 26-29, 1993; Abstract-Book p.50


1993 - Mueck A.O., Bueber V., Deuringer F.U.: Long-term treatment with transdermal estradiol correlation between plasma estradiol and bone densitiy. North American Menopause Society, 4th Congr., San Diego (USA), Sept. 2-4, 1993; Abstract-Book No. 12


1993 - Mueck A.O., Deuringer F.U., Lotz M., Lippert T.H.: Progestin dose-finding for continuous combined transdermal estradiol/oral norethisterone acetate therapy. 7th World Congr. Menopause, Stockholm (Sweden), June 20-24, 1993; Parthenon Publishing Carnforth (U.K.), Abstract-Book No. 341


1993 - Mueck A.O., Deuringer F.U., Weber E., Lippert T.H.:Norethisterone acetate vs. chlormadinone acetate sequentially with transdermal estradiol - bleedings, tolerability and acceptance. Internat. Symposium on Women's Health in Menopause, Milano (Italy), Sept 26-29, 1993; Abstract-Book p.49


1993 - Mueck A.O., Deuringer F.U.: Transdermal estradiol for preventing postmenopausal bone loss-effects of biochemical markers of bone metabolism. a) 23th Europ. Symp. on Calcified Tissues, Heidelberg (Germany), April 25-29, 1993; Springer Internat., Heidelberg, New York, Abstract No. 366 b) Calcif.Tissue Int., 1993; 52 (Suppl 1): S 92.


1993 - Mueck A.O., Salbach B., Deuringer F.U., Rabe T., Runnebaum B.: Low dose norethisterone acetate and cardiovascular system: coagulation and carbohydrate metabolism. World Congr. Osteoporosis, 4th Internat.Symp.and Consensus Development Conference, Hongkong, March 27 - April 2, 1993; Gardiner-Caldwell Publications (ed. C.Christiansen), Abstract No. 197


1993 - Mueck A.O., Salbach B., v.Holst T., Rabe T., Deuringer F.U., Runnebaum B.: Lipid metabolic effects of sequential vs. continuous combined transdermal estradiol/oral progestin treatment in postmenopausal women. a) Deutsche Gesellsch. f. Endokrinologie, 37.Symp., Berlin, 3.-6.März 1993 b) Experim. Clin. Endocrinology 1993; 101 (Suppl.1): 144.


1994 - Deuringer F.U., Mueck A.O., Lippert T.H.: Continuous Combined Estrogen/Progestin - Three regimens with transdermal estradiol. a) 14th World Congr.Gynecol.Obstetrics (FIGO), Montreal (Canada) Sept. 24-30, 1994 b) Internat.J.Obstet.Gynecol. 1994; 46(Suppl.1): 121


1994 - Deuringer F.U., Mueck A.O., Melchert F., Weber E., Lippert T.H.: Behandlung der Östrogenmangelkolpitis mit zyklischem oder kontinuierlichem transdermalem Östradiol und sequentiellem oralem Chlormadinonacetat. a) Menopausenkongress deutschsprachiger Länder, Wien (Österreich) 26.-28. Mai 1994 b) J.Menopause, 1994; 1: 21


1994 - Eicher W., Mueck A.O., Deuringer F.U., Lippert T.H.: Transdermal estradiol in the treatment of estrogen-deficiency related sexual disorders. a) 14th World Congr.Gynecol.Obstetrics (FIGO), Montreal (Canada) Sept. 24-30, 1994 b) Internat.J. Obstet.Gynecol. 1994; 46(Suppl.1): 6


1994 - Melchert F., Mueck A.O., Deuringer F.U., Lippert T.H.: Transdermal estradiol and chlormadinone acetate orally in urogynecologic disorders. a) 14th World Congr.Gynecol.Obstetrics (FIGO), Montreal (Canada) Sept. 24-30, 1994 b) Internat.J.Obstet.Gynecol. 1994; 46(Suppl.1): 1


1994 - Mueck A.O., Deuringer F.U., Melchert F., Weber E., Lippert T.H.: Endometriale Histologie und uterines Blutungsmuster unter kontinuierlicher transdermaler Östradiolsubstitution mit sequentiellem oralem Chlormadinonacetat. a) Menopausenkongr. deutschsprach. Länder, Wien (Österreich) 26.-28. Mai 1994 b) J.Menopause 1994; 1: 26-27


1994 - Rabe T., Mueck A.O., Deuringer F.U., Weber E.: Estradiol patch and 2-monthly vs. 3-monthly progestin - new regimens in postmenopause. a) 14th World Congr.Gynecol.Obstetrics (FIGO), Montreal (Canada) Sept. 24-30, 1994 b) Internat.J.Obstet.Gynecol. 1994; 46(Suppl.1): 122


1995 - Deuringer F.U., Bueber V., Mueck A.O.: Transdermal estradiol replacement (ETTS) for prevention of bone loss - only with monitoring of estradiol?. Europ.Assoc.Gynecol.Obstet. (EAGO), 10th Congress, Monte-Carlo (Monaco), March 29 - April 1, 1995; Abstract-Book p.130


1995 - Deuringer F.U., Mueck A.O., Roemer T., Lippert T.H.: Progestional effectivety of chlormadinone acetate (CMA) sequentially combined with transdermal estradiol replacement (ETTS). Europ.Assoc.Gynecol.Obstet. (EAGO), 10th Congr., Monte-Carlo (Monaco), March 29 - April 1, 1995; Abstr-Book p.131


1995 - Deuringer F.U., Mueck A.O., Roemer T., Lippert T.H.: Progestional effectivety of chlormadinone acetate (CMA) sequentially combined with transdermal estradiol replacement (ETTS). Europ.Assoc.Gynecol.Obstet. (EAGO), 10th Congr., Monte-Carlo (Monaco), March 29 - April 1, 1995; Abstr-Book p.131


1995 - Mueck A.O., Salbach B., Rabe T., v.Holst T., Deuringer F.U., Runnebaum B.: Transdermal hormonal replacement: long-term effects on lipids and carbohydrates. a) Deutsche Gesellsch. f. Endokrinologie, 39.Symp., Leipzig, 1. - 4.März 1995 b) Experim. Clin. Endocrinology Diabetes 1995; 103(Suppl.1): 44


1995 - Mueck A.O., Svoboda O., Deuringer F.U.: Transdermal estradiol (ETTS) for treatment of migraine caused by interruption of oral contraceptives (OC) or oral hormonal replacement therapy (HRT). Europ.Assoc.Gynecol.Obstet. (EAGO), 10th Congr., Monte-Carlo (Monaco), March 29 - April 1, 1995; Abstr-Book p.132


1995 - Mueck A.O., Weber E., Deuringer F.U., Rabe T., Lippert T.H., Runnebaum B.: Transdermal hormonal replacement in peri- and postmenopause: bleeding patterns with different progestin regimens. a) 4th World Congr. Gynecol.Endocrinology (ISGE), Madonna di Campiglio (Italy), Febr. 12-19, 1995, Abstract No. P10 b) Gynecol.Endocrinology 1995 (Suppl.1): 10


1995 - Rabe T., Mueck A.O., Salbach B., v.Holst T., Deuringer F.U., Runnebaum B.: Transdermal hormonal replacement: Long-term effects on lipids and carbohydrates using norethisterone acetate sequentially or continuously. a) 4th World Congress Gynecol.Endocrinology (ISGE), Madonna di Campiglio (Italy), February 12-19, 1995 b) Gynecol.Endocrinology 1995; 9(Suppl.1): 9


1996 - Mueck A.O., Melchert F., Deuringer F.U., Roemer T., Seeger H., Lippert T.H.: Transdermal estradiol replacement using chormadinone acetate as sequential progestogen. a) 8th World. Congr. Menopause, Sydney (Australia), 3-7 Nov. 1996 b) Maturitas 1997; 27 (Suppl.): 211


1996 - Mueck A.O., Rabe T., Salbach B., v.Holst T., Deuringer F.U., Runnebaum B.: Hormonsubstitution zur Verbesserung des Lipipprofiles in der Postmenopause. a) Deutsche Gesellsch. f. Kardiologie, Gießen, 19.-21.Sept.,1996 b) Zeitschrift f. Kardiologie 1996; 85 (Suppl.5) : 60


1997 - Mueck A.O., Seeger H., Deuringer F.U., Lippert T.H.: Blood pressure during different hormonal replacement regimens in climacteric patients. a). Deutsche Ges.. f. experim. u. klin. Pharmakologie u. Toxikologie, 38th Spring Meeting, Mainz, March 11-13, 1997 b) Naunyn Schmiedeberg's Arch.Pharmacol.Toxicol. 1997; 355 (Suppl.1) : 115


1997 - Mueck A.O., Seeger H., Gräser T., Deuringer F.U., Oettel M., Lippert T.H.: Chlormadinone acetate sequentially combined with oral or transdermal estradiol replacement: Effect on blood pressure in climacteric patients. a) Deutsche Gesellsch. f. experim. u. klin. Pharmakologie u. Toxikologie, Wien (Österreich), 14.-17.Sept. 1997 b) Naunyn Schmiedeberg's Arch.Pharmacol.Toxicol. 1997; 356 (Suppl.) : R5-R6


1998 - Mueck A.O., Rabe T., Salbach B., v.Holst Th., Seeger H., Deuringer F.U., Runnebaum B.: Sequentielle versus kontinuierliche Gestagenkombination bei Östrogenbehandlung postmenopausaler Frauen - Langzeiteffekte auf Gerinnung und Fibrinolyse. a) Deutsche Gesellschaft für Kardiologie, 22.Herbsttagung, Leipzig, 22.-24.Oktober 1998 b) Zeitschrift f. Kardiologie 1998; 87 (Suppl. 5): 54


1999 - Deuringer F.U., Mueck A.O., Mueck S., Seeger H., Lippert T.H.: Blood pressure during hormonal replacement therapy (HRT) - cyclic vs. continuous transdermal estradiol. a) German Society of Endocrinology, 43rd Annual Meeting, Kiel, March 10-13, 1999 b) Exp. Clin. Endocrinol. Diabetes 1999; 107 (Suppl.1): S50


1999 - Deuringer F.U., Mueck A.O., Mueck S., Seeger H., Roemer Th., Wallwiener D.: Progestin effect on blood pressure during combination with transdermal estradiol – chlormadinone acetate vs. norethisterone acetate. a) Word Congr. on the Menopause, 9th Internat.Meeting, Yokohama (Japan), Oct. 17-21, 1999 b) Climacteric 1999; 2 (Suppl.1): 203


1999 - Eicher W., Kuckatz C., Deuringer F.U., Mueck A.O.: Estrogen replacement after hysterectomy – hormonal profile and postoperative complaints in premenopausal patients with and without additional oophorectomy. a) Word Congr. on the Menopause, 9th Internat.Meeting, Yokohama (Japan), Oct. 17-21, 1999 b) Climacteric 1999; 2 (Suppl.1): 332


1999 - Mueck A.O., Seeger H., Deuringer F.U., Lippert T.H.: Vascular effects of estradiol combined with the lipid-lowering drug fluvastatin. a) Word Congr. on the Menopause, 9th Internat.Meeting, Yokohama (Japan) Oct. 17-21, 1999 b) Climacteric 1999; 2 (Suppl.1): 225


1999 - Mueck A.O., Seeger H., Deuringer F.U., Mueck S., Lippert T.H.: Continuous combined hormone replacement therapy in postmenopausal women: Comparison of conventional oral application with a new combi-patch. a) British/German Pharmacological Societies, Joint Meeting, Nottingham (U.K.), July 13-16, 1999 b) Br.J.Clin.Pharmacology 1999 (Suppl.): P176


1999 - Mueck A.O.,Mueller M.M. Güldner A., Seeger H., Deuringer F.U., Lippert T.H. Bioavailability of two estradiol/norethisterone preparations for hormonal replacement therapy (HRT) in postmenopausal women a) Deutsche Gesellsch. f. experim. u. klin. Pharmakologie u. Toxikologie, Mainz; March 9-11, 1999 b) Naunyn Schmiedeberg's Arch.Pharmacol.1999; 359 (Suppl.): R136


2000 - Deuringer F.U., Schneidereit R., Müller A., Römer Th., Mueck A.O.: Continuous combined estradiol/norethisterone: efficacy and compliance assessed in 2.907 patients. a) 16th World Congr. of Gynecology and Obstetrics (FIGO), Washington D.C. (USA) Sept. 3-8, 2000 b) Int. J. Gynecol. Obstet. 2000; 70 (Suppl. 2): 146


2000 - Deuringer F.U., Schneidereit R., Roemer Th. Mueck A.O.: Estradiol/sequential norethisterone: Adverse events in 3.602 patients. a) 5th European Congr. on Menopause, Copenhagen (Denmark), July 1-5, 2000 b) Maturitas 2000; 35 (Suppl.): S85


2000 - Deuringer F.U., Seeger H., Gräser Th., Mueck A.O.: Effekt zweier oraler Kontrazeptiva auf cGMP als Marker für vasoaktive Wirkungen. a) Deutsche Gesellsch. für Gynäkologie u. Geb.hilfe, 53. Kongress, 13.-17. Juni, München b) Geburtsh. Frauenheilk. 2000; 60 (S1): S86


2000 - Deuringer F.U., Seeger H., Wallwiener D., Mueck A.O.: Effect of estradiol and statin on adhesion molecules and vasoactive mediators in human endothelial cell cultures. a) North American Menopause Soc., Orlando, Sept. 7-9; 2000 b) Menopause (J.North Am. Menopause Soc.) 2000: 7 (6): 438


2000 - Mueck A.O., Deuringer F.U., Seeger H., Römer Th.: Vaginalsonographische Bewertung einer östrogenbedingten Endometriumproliferation und Effekt einer Gestagenzugabe bei spät-postmenopausalen Frauen. a) Dt. Menopausengesellschaft, 4. Jahrestagung, 3.-4.11.2000 b) J. Menopause 2000; 4 (Suppl.): 6-7


2000 - Mueck A.O., Deuringer F.U., Seeger H., Wallwiener D.: Östradiol/Norethisteronacetat kontinuierlich kombiniert in der Postmenopause: Amenorrhoe-Raten in Abhängigkeit von Applikationsform, Dosis und Menopausenintervall. a) Dt. Menopausengesellschaft, 4. Jahrestagung, 3.-4.11.2000 b) J. Menopause 2000; 4 (Suppl.): 7-8


2000 - Mueck A.O., Deuringer F.U., Seeger H., Wallwiener D.: Transdermal estradiol/oral progestin: Blood pressure in 13.910 patients. a) 5th European Congr. on Menopause, Copenhagen (Denmark), July 1-5, 2000 b) Maturitas 2000; 35 (Suppl.): S63


2000 - Mueck A.O., Schneidereit R., Deuringer F.U., Roemer Th.: Estradiol/sequential norethisterone: Bleedings patterns in 2.990 patients. a) 5th European Congr. on Menopause, Copenhagen (Denmark), July 1-5, 2000 b) Maturitas 2000: 35 (Suppl.): S84


2000 - Mueck A.O., Schneidereit R., Müller A., Deuringer F.U., Römer Th.: Continuous combined estradiol/norethisterone: adverse events assessed in 2.907 patients. a) 16th World Congr. of Gynecology and Obstetrics (FIGO), Washington D.C. (USA) Sept. 3-8, 2000 b) Int. J. Gynecol. Obstet. 2000; 70 (Suppl. 2): 146


2000 - Mueck A.O., Seeger H., Deuringer F.U., Lüdtke R., Graeser T., Wallwiener D.: Effect of HRT on vasoactive markers: estradiol vs. progestin/estradiol treatment. a) 5th European Congr. on Menopause, Copenhagen (Denmark), July 1-5, 2000 b) Maturitas 2000: 35 (Suppl.): S62-63


2000 - Mueck A.O., Seeger H., Deuringer F.U., Wallwiener D.: Angiogenetic In-Vitro effects of endogenous 17ß-estradiol metabolites. a) North American Menopause Soc., Orlando, Sept. 7-9; 2000 b) Menopause (J.North Am. Menopause Soc.) 2000; 7(6): 437


2000 - Schneidereit R., Deuringer F.U., Müller A., Römer Th., Mueck A.O.: Continuous combined estradiol/norethisterone: bleeding pattern assessed in 2.287 patients. a) 16th World Congr. of Gynecology and Obstetrics (FIGO), Washington D.C. (USA) Sept. 3-8, 2000 b) Int. J. Gynecol. Obstet. 2000; 70 (Suppl. 2): 146-147


2000 - Schneidereit R., Deuringer F.U., Roemer Th., Mueck A.O.: Estradiol/sequential norethisterone: efficacy and compliance in 3.602 patients. a) 5th European Congr. on Menopause, Copenhagen (Denmark), July 1-5, 2000 b) Maturitas 2000; 35 (Suppl.): S68-69


2001 - Deuringer F.U., Seeger H., Gräser Th, Wallwiener D., Mueck A.O.: Wirkung des Gestagens Dienogest auf die Produktion vasoaktiver Marker bei Einsatz in der Hormonsubstitution und in der oralen Kontrazeption. a) Dt. Menopausengesellschaft, Jahrestagung, Dresden, 21.-22.Sept. 2001 b) J. Menopause 2001; 8 (3): 39


2001 - Mueck A.O., Seeger H., Deuringer F.U., Gräser T., Wallwiener D.: Influence of postmenopausal hormone replacement therapy and oral contraceptives on endogenous estradiol metabolism. a) British Menopause Society; Annual Meeting, Birmingham (UK), June 28-29, 2001 b) J.Br.Menopause Soc. 2001;7 (Suppl.3): 29-30


2001 - Mueck A.O., Seeger H., Deuringer F.U., Wallwiener D.: Effect of tibolone on markers of coronary endothelial function in human female endothelial cell cultures. a) British Menopause Society; Annual Meeting, Birmingham (UK), June 28-29, 2001; b) J.Br.Menopause Soc. 2001; 7 (Suppl.3): 29


2001 - Seeger H., Deuringer F.U., Wallwiener D., Mueck A.O.: Wirkung des neuen Gestagens Dienogest in Kombination mit Estradiol auf die vaskuläre PAI-1 und MCP-1 Produktion. a) Dt. Gesellschaft für Kardiologie u. Herz/Kreislaufforschung, Ulm, 27.-29.Sept. 2001 b) Z. Kardiologie (German J. Cardiology) 2001; 90 (Suppl.5): 142


2001 - Seeger H., Wallwiener D., Deuringer F.U., Mueck A.O.: Effect of estradiol metabolites on the proliferation of human female osteoblastic cells. a) North American Menopause Society; 12th Annual Meeting, New Orleans, Oct. 4-6, 2001 b) Menopause (J.North Am. Menopause Society) 2001; 8: 456


2001 - Seeger H., Wallwiener D., Deuringer F.U., Mueck A.O.: Effect of statins on human breast cancer cell proliferation. a) Dt. Gesellschaft für Klin. Pharmakologie; 3. Jahreskongr., 15.-17.11.2001; Köln b) Europ. J. Clin. Pharmacology 2001; 57 (8): A27


2003 - Deuringer FU, Seeger H, Huober J, Mueck AO. The endogenous estradiol metabolite 2-methoxyestradiol inhibits aromatase activity as effective as the aromatase-inhibitor letrozole. a) 6th European Congress on Menopause (EMAS); Bucharest (Romania), May 24-28; 2003 b) Maturitas 2003; 44 (Suppl.2): S151


2003 - Mueck AO, Seeger H, Deuringer FU, Huober J. Chemotherapy of breast cancer – additive anticancerogenic effects by 2-methoxyestradiol? a) 6th European Congress on Menopause (EMAS); Bucharest (Romania), May 24-28; 2003 b) Maturitas 2003; 44 (Suppl.2): S94


2003 - Mueck AO, Seeger H, Deuringer FU, Wallwiener D. 'Pulsed' estradiol action can stimulate breast cancer proliferation. a) 6th European Congress on Menopause (EMAS); Bucharest (Romania), May 24-28; 2003 b) Maturitas 2003; 44 (Suppl.2): S94


2003 - Mueck AO, Seeger H, Deuringer FU, Wallwiener D. Short-time estradiol application acts proliferative in human breast cancer cells. a) North American Menopause Society, 14th Annual Meeting, Miami (USA), Sept 17-20, 2003 b) Menopause (J. North Am. Menopause Society) 2003; 10: 570


2003 - Seeger H, Deuringer FU, Wallwiener D, Mueck AO. Breast cancer risk during HRT: influence of estradiol metabolites on tumor growth and neoangiogenesis. a) 6th European Congress on Menopause (EMAS); Bucharest (Romania), May 24-28; 2003 b) Maturitas 2003; 44 (Suppl.2): S126 (Posterpreis!)


2003 - Seeger H, Deuringer FU, Wallwiener D, Mueck AO. Does stroma have an important influence on the proliferation of human breast cancer cells? a) 6th European Congress on Menopause (EMAS); Bucharest (Romania), May 24-28; 2003 b) Maturitas 2003; 44 (Suppl.2): S126-S127


2003 - Seeger H, Huober J, Deuringer FU, Mueck AO. The endogenous estradiol metabolite 2-methoxyestradiol is a potent aromatase inhibitor. a) North American Menopause Society, 14th Annual Meeting, Miami (USA), Sept 17-20, 2003 b) Menopause (J. North Am. Menopause Society) 2003; 10: 570


2004 - Deuringer FU, Seeger H, Huober J, Mueck AO. 2-Methoxy-estradiol may be superior to tamoxifen as preventive agent for breast cancer in high risk women. a) Kongress Menopause Andropause Anti-Aging Wien, Jahreskongress 2004; 2.-4.Dezember, 2004 - b) J Menopause 2004; 11(4): 25 (Ausgabe für Österreich)


2004 - Krämer E, Seeger H, Deuringer FU, Mueck AO. Possible influence of stromal derived growth factors on progestogen-induced human breast cancer cell proliferation. a) North American Menopause Society (NAMS), 15th Annual Meeting, Washington D.C. (USA), Oct 6-9 2004 - b) Abstract-Book 2004; p. 72 (P-21); Menopause 2004; in press


2004 - Mueck AO, Deuringer FU, Seeger H. Catecholestrogens and proliferation on normal versus cancerous human breast cells. a) North American Menopause Society (NAMS), 15th Annual Meeting, Washington D.C. (USA), Oct 6-9 2004 - b) Abstract-Book 2004; p. 72 (P-22); Menopause 2004; in press;


2004 - Mueck AO, Krämer EA, Deuringer FU, Seeger H. Progestogens act differently on cancerous and non-cancerous breast cells. a) Kongress Menopause Andropause Anti-Aging Wien, Jahreskongress 2004; 2.-4.Dezember, 2004 - b) J Menopause 2004; 11(4): 24 (Ausgabe für Österreich)


2004 - Mueck AO, Seeger H, Deuringer FU, Huober J, Wallwiener D. Are estradiol metabolites involved in breast carcinogenesis? A case-control study. a) Kongress Menopause Andropause Anti-Aging Wien, Jahreskongress 2004; 2.-4.Dezember, 2004 - b) J Menopause 2004; 11(4): 25 (Ausgabe für Österreich)


2004 - Seeger H, Deuringer FU, Mueck AO. Tibolone is aromatized in human breast cancer cells and triggers increased cell proliferation. a) North American Menopause Society (NAMS), 15th Annual Meeting, Washington D.C. (USA), Oct 6-9 2004 - b) Abstract-Book 2004; p.72 (P-23); Menopause 2004; in press


2005 - Krämer E., Seeger H., Deuringer F.U., Mueck A.O.: Die Rolle der Gestagene beim Ovarialkarzinom – in vitro Untersuchungen. a) Dt. Menopause Gesellschaft, Jahrestagung, Münster; 17.-18.Juni 2005 b) J. Menopause 2005; 12: 13


2005 - Mueck A.O., Deuringer F.U., Seeger H.: Estradiol metabolites are proliferative factors for human breast cancer cells. a) Kongress Menopause – Andropause - Anti-Aging 2005 Wien; 8.-10.Dez. 2005 b) J. Menopause 2005; 12: 25


2005 - Mueck A.O., Krämer E., Deuringer F.U., Seeger H.: Influence of different progestogens on normal and cancerous human breast cells. a) Kongress Menopause – Andropause - Anti-Aging 2005 Wien; 8.-10.Dez. 2005 b) J. Menopause 2005; 12: 25